Novavax Inc. Stock
€6.21
Your prediction
Novavax Inc. Stock
Pros and Cons of Novavax Inc. in the next few years
Pros
Cons
Performance of Novavax Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novavax Inc. | -2.920% | -7.316% | -13.405% | -22.000% | -21.148% | -74.310% | -91.935% |
| Ardelyx Inc. | -1.100% | 0.927% | 22.918% | 21.038% | 5.217% | 327.776% | 6.743% |
| Krystal Biotech | 1.570% | 0.805% | 12.045% | -0.539% | 15.210% | 130.724% | - |
| Evolus Inc | 3.330% | 7.826% | 20.388% | -47.009% | -40.952% | -12.676% | 116.254% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.General Impression
The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.
Detailed Analysis
Comments
News
Novavax (NVAX) Profit Jumps on Milestone
Novavax (NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so
Novavax Stock: FDA Approval Triggers Financial Windfall
The U.S. Food and Drug Administration has granted full approval (Biologics License Application) for Novavax's COVID-19 vaccine Nuvaxovid, marking a significant breakthrough for the biotech company
